SCHEMBL27247331

SCHEMBL27247331

O=C(O)NCc1cc2cc(OC(F)(F)F)c(OCc3ccon3)cc2[nH]1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 2/20 0.34
▸ SRD5A1 P18405 1/20 0.32
▸ SRD5A2 P31213 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ KDM4A O75164 2/20 0.32
▸ KDM5A P29375 2/20 0.32
▸ FFAR1 O14842 1/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RXRA P19793 1/20 0.31
▸ RXRB P28702 1/20 0.31
▸ RXRG P48443 1/20 0.31
▸ PPARD Q03181 1/20 0.31
▸ ABL1 P00519 1/20 0.31
▸ MAP4K1 Q92918 1/20 0.30
▸ NTRK1 P04629 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30920547 0.89 CACNA1H (0.37) KLKB1SRD5A1SRD5A2SMN1; SMN2KDM4A
SCHEMBL27247553 0.87 IKBKB (0.33) KLKB1SMN1; SMN2RAB9ANPC1
SCHEMBL30920828 0.87 EPHX2 (0.37) KLKB1
SCHEMBL27247685 0.87 EPHX2 (0.37) KLKB1
SCHEMBL27247742 0.84 KLKB1 (0.31) KLKB1SRD5A1SRD5A2SMN1; SMN2FFAR1
Hydrochloric Acid SCHEMBL27246740 0.82 LOXL2 (0.33) —
SCHEMBL27247213 0.82 SCD (0.33) KLKB1SRD5A1SRD5A2SMN1; SMN2FFAR1
SCHEMBL27247732 0.79 MTNR1A (0.40) KLKB1SMN1; SMN2RAB9ANPC1MAP4K1
SCHEMBL30946221 0.78 MTNR1A (0.40) SMN1; SMN2KDM5ARAB9ANPC1KDM4E
SCHEMBL27247741 0.78 MTNR1A (0.40) SMN1; SMN2KDM5ARAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 KLKB1 3876/4885SRD5A1 772/4885SRD5A2 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback